Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Cheminformatics Suite

October 17, 2011 7:37 am | Product Releases | Comments

Accelrys Inc. announced its Cheminformatics Suite, providing R&D organizations with end-to-end solution available to register, search, mine, and analyze information on chemical structures and reactions, chemically modified sequences, and associated data.


Vortex Mixer

October 17, 2011 7:29 am | Product Releases | Comments

Benchmark Scientific has introduced an addition to their vortex mixer line. The Mortexer features a multifunctional re-imagining of the standard cup-head found in traditional vortex mixers.


Steven Carr Receives Agilent Award

October 17, 2011 7:15 am | News | Comments

Agilent Technologies Inc. and the Agilent Technologies Foundation announced that Steven Carr, PhD, who directs the Proteomics Platform at the Broad Institute of MIT and Harvard, has been selected for an Agilent Thought Leader Award.


Teva Completes $6.8B Cephalon Deal

October 17, 2011 7:12 am | News | Comments

Generic drugmaker Teva Pharmaceutical Industries Ltd. said that it has closed its $6.8 billion acquisition of drug maker Cephalon Inc., a week after the U.S. Federal Trade Commission cleared the deal.


Baxter Begins Phase Trial of BAX 111

October 17, 2011 7:09 am | News | Comments

Baxter International Inc. announced a Phase 3 trial to evaluate the safety and effectiveness of BAX 111, an investigational recombinant von Willebrand factor, for the treatment and prevention of bleeding episodes in patients with von Willebrand disease.


FDA Clears HSV Assay

October 17, 2011 7:03 am | News | Comments

BioHelix Corporation has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s first molecular diagnostic assay, the IsoAmp HSV Assay.


Preview of J & J Earnings Report

October 17, 2011 6:58 am | News | Comments

Health care giant Johnson & Johnson likely will discuss its pipeline, recent drug approvals and several important deals when it reports its third-quarter results before the stock market opens Tuesday.


Roche Buying Anadys for $230M

October 17, 2011 6:53 am | News | Comments

Swiss drugmaker Roche Holding AG announced it is paying $230 million to take over Anadys Pharmaceuticals Inc., a U.S.-based specialist in the development of hepatitis C treatments.


Acura to Receive Royalties for Oxecta

October 17, 2011 6:42 am | News | Comments

Acura Pharmaceuticals Inc. said that it is eligible to receive tiered royalty payments from Pfizer Inc. on sales of the painkiller Oxecta, which uses Acura technology to discourage abuse of the drug.


Epizyme Hits $4M Milestone

October 14, 2011 7:55 am | News | Comments

Epizyme, Inc. announced the achievement of pre-clinical milestones in its alliance with GlaxoSmithKline, triggering $4 million in milestone payments.


Watson Files Application for Generic Daytrana

October 14, 2011 7:47 am | News | Comments

Watson Pharmaceuticals Inc. said it filed an application with the Food and Drug Administration to make a generic version of Noven Pharmaceticals' attention deficit and hyperactivity disorder treatment Daytrana.


Oral Calcitonin Fails to Meet Endpoints

October 14, 2011 7:38 am | News | Comments

Emisphere Technologies, Inc. reported that Novartis Pharma AG provided information about their Phase 3 study assessing the safety and efficacy of oral calcitonin in the treatment of osteoarthritis of the knee.


NHLBI Funds Successful Sickle Cell Research

October 14, 2011 7:16 am | News | Comments

National Institutes of Health-funded scientists have corrected sickle cell disease in adult laboratory mice by activating production of a special blood component normally produced before, but not after, birth.

NIH Funds Development of Broad-Spectrum Therapeutics

October 14, 2011 5:12 am | News | Comments

Four companies are to develop broad-spectrum therapeutics — antibiotics, antivirals, and an antitoxin — to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases.


Serada Falls Short in Phase 3 Trial

October 14, 2011 5:05 am | News | Comments

Depomed said its experimental treatment for menopausal hot flashes did not meet all the goals of its trial. The study compared Serada to a placebo and was designed to determine if the drug reduced the frequency and severity of hot flashes.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.